



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 13, 2024

Robert E. Hoffman  
Chief Executive Officer  
Kintara Therapeutics, Inc.  
9920 Pacific Heights Blvd, Suite 150  
San Diego, CA 92121

**Re: Kintara Therapeutics, Inc.**  
**Registration Statement on Form S-4/A**  
**Exhibit Nos. 10.37, 10.38, 10.39, 10.40 and 10.41**  
**Filed August 12, 2024**  
**File No. 333-279368**

Dear Robert E. Hoffman:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences